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Background
During the chronic myelogenous leukemia (CML) the
Bcr-Abl oncoprotein is produced, which leads to unre-
gulated cell proliferation. CML is treated with one of
several targeting therapies such as imatinib, (formerly
STI-571 [Glivec; Novartis, Switzerland]) a selective inhi-
bitor that blocks tyrosin kinase activity of the Bcr-Abl
oncoprotein. Apart from the second generation Bcr-Abl
inhibitors, identifying novel direct or indirect down-
stream targets of Bcr-Abl could contribute significantly
to the development of new synergistic treatment strate-
gies against CML. The effects of imatinib on the protein
expression of Bcr-Abl positive cells are being investi-
gated [1]. A protein which is downregulated during
treatment with imatinib (eukaryotic translation initiation
factor eIF5A) was identified. This protein is a potentially
promising target for single-agent and combined-treat-
ment strategies for CML. For protein complex identifi-
cation a high cell number is needed. This is difficult to
be obtained reproducibly with flask cultures or roller
bottles. The aim of this project was to develop and
establish a reproducible bioreactor cultivation of murine
suspension cell lines (BA/F3 p210), which yields a total
cell number close to 1·10
10 cells required for analytics.
Cells should be in exponential growth under constant
culture conditions at the time of harvest. A small stirred
tank bioreactor with a working volume of 150 mL was
used to study and compare different operation modes:
batch, fed-batch and continuous. Cell growth and glu-
cose consumption were assessed as main culture
parameters.
Material and methods
Cell lines: BA/F3 p210 and BA/F3 p210 eIF5A-2 (BA/
F3 = mouse pro B cells, p210 = Bcr-Abl oncoprotein
(210kDa), eIF5A-2 = isoform of the eukaryotic transla-
tion initiation factor eIF5A).
In a first step, a working cell bank was established and
cell growth was characterized in T-flasks. Afterwards,
different cultivation modes were tested in a stirred tank
bioreactor (Vario1000, Medorex, Germany) as follows:
batch: Cultivation volume Vstart = 350 mL, duration:
40 h
fed-batch: Cultivation volume Vstart =3 4 5m L ,d u r a -
tion: 64 h, Feeding took place every time Glucose con-
centration fell below 2 mM. Feed medium consisted on
a mixture of batch medium and higher concentrations
of glucose and glutamine.
Continuous: Cultivation volume Vstart = 115 mL, dilu-
tion rate D = 0.049 h
-1 duration: 118.5 h.
The scale-up experiment was performed in a 5 L stir-
red bench-top bioreactor (Biostat B, Sartorius Stedim
Biotech GmbH) with pH and DO control.
Results and conclusions
In batch mode, the maximum viable cell density during
exponential growth was VCDmax = 14.7·10
5 cells mL
-1.
In fed-batch mode VCDmax = 22.6·10
5 cells mL
-1.T h i s
higher cell density is an advantage over the batch cul-
ture mode. It was not possible to obtain higher cell den-
sities in this mode, since the feed medium consisted on
a formulation for batch culture with further addition of
glucose and glutamine. In continuous mode the highest
possible cell density was maintained in the bioreactor, in
order to produce continuously cells for further treat-
ment. A maximum cell yield of 8.3·10
6 cells h
-1 could be
harvested from the bioreactor. After scale-up, this yield
might be increased, so that the needed cell number
could be harvested in only few days. A disadvantage of
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reproduction in any medium, provided the original work is properly cited.Figure 1 Schematic diagram of the final batch process in a 5 L bioreactor that yields a total cell number close to 1·10
10
Figure 2 Vstart = 5090 mL, max. viable cell density in exponential growth after 39.5 hours VCDmax = 18.1·10
5 cells mL
-
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Page 2 of 3the continuous process with cell harvest was observed
for the storage process, since cell lysis took place after
storage at 4 °C.
A first approach for scale-up was performed in the 5 L
bioreactor (Figure 1), where the maximum cell density
during exponential phase allowed for the needed cell
number. Regarding the required reproducibility for culti-
vation, the 5 L batch mode was preferred over T-flasks
due to the possibility for control of process variables
like pH and pO2.
Compared to T-flasks, glucose uptake during bioreac-
tor cultivation was much higher, which led to lower
final-cell-density yields. fed-batch and continuous modes
were firstly favored due the theoretical final cell num-
bers reached during culture. However, the difference in
growth, limitation of bioreactor volume and the need of
a special medium formulation for higher cell densities
during fed-batch, limited the final yield. Continuous
mode with temperature reduction of harvested cells
allowed for constant cell production in exponential
phase. On the other hand, storage of intact cells was
limited probably due to protease action. The 150 mL
batch cultivation was scaled up to 5 L in a stirred
bench-top bioreactor (Biostat B, Sartorius Stedim Bio-
tech GmbH).
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